Details of the oral presentations are listed below, and the full abstracts are available on the ASGCT meeting website.
Title: | Toxicology, Pharmacokinetics and Biodistribution of a PATrOL™-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1 | |
Presenter: | Dr. | |
Presentation Time: | ||
Session Date/Time: | ||
Session Title: | Gene Therapy Approaches for Muscle and Skeletal Diseases | |
Room: | Room 408 AB | |
Abstract Number: | 131 | |
Title: | Nuclease-Free Gene Editing with Peptide Nucleic Acids: A New Class of In | |
Presenter: | Dr. | |
Presentation Time: | ||
Session Date/Time: | ||
Session Title: | Genome & Epigenome Editing Technologies II | |
Room: | Concourse Hall 152 & 153 | |
Abstract Number: | 335 | |
About
NeuBase is a pre-clinical stage biopharmaceutical company leveraging its peptide-nucleic acid technology to accelerate the genome editing revolution. NeuBase's Stealth Editing™ technology is a new type of gene editing designed to avoid being identified by the immune system and provide pronounced effects that are safe, delivered with non-viral technologies, and broadly applicable across different mutation types and industries. This in vivo gene editing system seeks to address disease at the base level by recruiting the body’s own editing machinery to correct mutations that cause disease. The Company projects that its technology can potentially address up to ~90% of all known human mutations, including insertions, deletions, transitions, and transversions with a simple non-immunogenic solution. To learn more, visit www.neubasetherapeutics.com.
Use of Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by the use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” “project,” or “intend,” the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the potential and prospects of the Company’s proprietary PATrOL™ platform or Stealth Editing™ technology. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the
NeuBase Investor Contact:
Managing Director
daniel@lifesciadvisors.com
OP: (617) 430-7576
Source:
2023 GlobeNewswire, Inc., source